Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

A small subgroup of advanced EC patients shows HRD positivity by gLOH or HRDsig, potentially identifying those most likely to benefit from PARP inhibitors. These tumors are typically endometrioid with TP53 mutations.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2025-12-01
DOI
https://doi.org/10.1016/j.esmoop.2025.105919
Citations
1
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
2.06
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

Stefano Tamberi, Alberto Farolfi, Saverio Cinieri, Anna Passarelli et al.
1 citations
ESMO Open
Endometrial and Cervical Cancer Treatments
2.06
article

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

Stefano Tamberi, Alberto Farolfi, Saverio Cinieri, Anna Passarelli, Ethan Sokol, Laura Arenare, Carmela Pisano, V. Ghizzoni, Michele Bartoletti, Claudia De Angelis, Daniela Califano, Claudio Andreetta, Clorinda Schettino, Rossella De Cecio, Domenica Lorusso, Saumya D. Sisoudiya, Anna Spina, Anna Fagotti, Daniela Russo, Giovanni Luca Scaglione, Filippo Greco, Francesco Perrone, S Pignata
article en
1 citations

Abstract

A small subgroup of advanced EC patients shows HRD positivity by gLOH or HRDsig, potentially identifying those most likely to benefit from PARP inhibitors. These tumors are typically endometrioid with TP53 mutations.

ESMO OpenVol. 10(12)
Humanitas University (IT), Boston Foundation (US), Agostino Gemelli University Polyclinic (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale A. Perrino (IT), Azienda Unità Sanitaria Locale Della Romagna (IT), Istituto Dermopatico dell'Immacolata (IT), Ospedale Santa Maria della Misericordia di Udine (IT), Centro di Riferimento Oncologico (IT), Regione del Veneto (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University of Naples Federico II (IT)
Openalex Percentile: Top 10%
Endometrial and Cervical Cancer Treatments
2.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.